Tuesday, March 28, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Patent Granted for Anthrax Elimination System

by Global Biodefense Staff
February 5, 2014

In addition to the patents held for healthcare-based enclosed space disinfection applications, Medizone International, Inc. has now been awarded a patent for its government variant of AsepticSure, intended for use by defense agencies as a response to a biological attack on critical buildings, infrastructure and resources.

“We have been successful in completely eliminating Bacillus atropheus and Bacillus subtilis, both internationally recognized study surrogates for Anthrax, one of the most difficult weaponized pathogens to kill,” explained Dr. Michael E. Shannon, Medizone International’s President. “Being able to eliminate these surrogates for Anthrax with our technology almost assures we now have the ability to remediate critical public infrastructure following a biological attack and restore it to service without damaging important and expensive equipment including communications systems.  Militaries have struggled with this problem for decades and, until now, this simply has not been possible.”

“To now have patent protection granted for this system,” stated Edwin Marshall, Medizone’s CEO, “should allow the Company protected access to a potentially lucrative government market due to the unique capability of AsepticSure’s government variant.”

Medizone International, Inc. is a research and development company advancing systems to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. Medizone International’s BSL2A certified laboratory located at Innovation Park, Queen’s University in Kingston, Ontario, Canada, provides a primary research and development platform for the company.

Tags: AnthraxAwardsBioterrorismConsequence Management

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development
Industry News

DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development

January 10, 2023
NIH Grant Awarded to Study Evolution of Lyme Disease Bacteria in Deer Ticks
Pathogens

NIH Grant Awarded to Study Evolution of Lyme Disease Bacteria in Deer Ticks

December 7, 2022
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC